Kean University has recently unveiled groundbreaking glioblastoma research that brings new hope in the fight against deadly high-grade brain cancer. The research focuses on genetically engineered macrophages that show promise in treating this challenging form of cancer.
According to a recent press release, the university is at the forefront of glioblastoma research, exploring innovative treatment options to combat this aggressive type of brain cancer. The use of genetically engineered macrophages represents a significant advancement in the field and offers hope for patients battling glioblastoma.
In a statement, a representative from Kean University stated, "Discover groundbreaking glioblastoma research at Kean University, where genetically engineered macrophages offer new hope for treating deadly high-grade brain cancer."
Furthermore, the university highlighted the dedication of a 30-year lab veteran who is leading the charge in finding cancer cures and enhancing human health. The veteran researcher's commitment to advancing research in the field of oncology underscores the importance of ongoing efforts to improve treatment options for cancer patients.
In the words of the university, "Hear from our 30-year lab veteran who is driven to find cancer cures and improve human health."
The ongoing research at Kean University signifies a significant step forward in the fight against glioblastoma and demonstrates the institution's commitment to making a tangible impact in the field of cancer research. The innovative approach of using genetically engineered macrophages holds promise for the future of treating this challenging disease. #GlioblastomaResearch #KeanUniversity
Alerts Sign-up